As is likely to be true in each of the next few months, here is another bolus of cases that Merck contends are ripe for dismissal. There is some dispute about some of them, so the able Judge Cogan, sitting in Brooklyn -- will have to enter a subsequent order deciding these matters. I'll attach the summary letter, of where things stands, just the same, tonight -- after yesterday's hearing (which we reported upon last night).
Here is the full six page letter -- and a bit of it:
. . . .As discussed during the conference, Merck submits this letter to bring to the Court’s attention seven cases in this MDL that Merck asserts are ripe for dismissal. Broadly speaking, each of these cases may be dismissed for one of three reasons. Merck addresses each case in detail below, but for the Court’s convenience, the cases and their respective reason for dismissal are summarized [inside the letter]. . . .
Now you know. Sleep well, all you small -- but growing cowboys, and cowgirls -- smile. . . .
नमस्ते
2 comments:
https://globenewswire.com/news-release/2018/03/05/1415327/0/en/Aduro-Announces-Milestone-Achieved-under-Merck-Collaboration-for-Initiation-of-Anti-CD27-Phase-I-Trial-in-Advanced-Solid-Tumors.html
good news~
Indeed -- great stuff for Aduro, particularly. It is early green shoots (Phase I), but still good to see -- I am hopeful.
In addition, Kenilworth announced a big new immuno-oncology deal with Easai (nearly $1 billion all in). . . but I am buried in the office until say 2 PM EST. . . so I won't likely get a post up before then. . . . the last 48 hours have been wall-to-wall, in my other life.
But all is good. Thanks again, Anon. Greatly appreciated, that you keep the fires banked, and burning here, while I am off for parts. . . unknown. . . smile.
Namaste
Post a Comment